BLASUBCUTANEOUSINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IRA Negotiated
PYZCHIVA (ustekinumab-ttwe) by Samsung Bioepis is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYZCHIVA (ustekinumab-ttwe) is a biosimilar monoclonal antibody that antagonizes interleukin-12, a key cytokine in immune-mediated inflammatory disorders. As a follow-on biologic, it replicates the mechanism of the reference product to treat conditions driven by IL-12 dysregulation. The subcutaneous formulation offers convenient patient dosing for chronic immunological diseases.
Growth
Early-stage growth asset with moderate competitive intensity (30% pressure) but significant IRA price reductions requiring aggressive market access and contracting expertise.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining PYZCHIVA offers exposure to biosimilar commercialization in a high-stakes, payer-focused environment where success hinges on contracting, clinical evidence translation, and formulary placement rather than pure launch innovation. The 64% IRA price cut (2024–2026) signals an early focus on volume-based market share gains and operational efficiency—ideal for professionals building payer negotiation and managed markets expertise.
Brand Manager
Worked on PYZCHIVA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.